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AbstrACt
Introduction Malignant peritoneal mesothelioma (MPM) 
is an uncommon but aggressive neoplasm and has a 
strong association with asbestos exposure. MPM has low 
survival rates of approximately 1 year even after (palliative) 
surgery and/or systemic chemotherapy. Recent advances 
in treatment strategies focusing on cytoreductive surgery 
(CRS) and hyperthermic intraperitoneal chemotherapy 
(HIPEC) have resulted in improved median survival 
of 53 months and a 5 year survival of 47%. However, 
recurrence rates are high. Current systemic chemotherapy 
in the adjuvant setting is of limited efficacy, while 
immunotherapy with dendritic cell based immunotherapy 
(DCBI) has yielded promising results in murine models 
with peritoneal mesothelioma and in patients with pleural 
mesothelioma.
Methods and analysis The MESOPEC trial is an 
open-label single centre phase II study. The study 
population are adult patients with histological/cytological 
confirmed diagnosis of epithelioid malignant peritoneal 
mesothelioma. Intervention: 4 to 6 weeks before CRS-
HIPEC a leukapheresis is performed of which the 
monocytes are used for differentiation to dendritic cells 
(DCs). Autologous DCs pulsed with allogeneic tumour 
associated antigens (MesoPher) are re-injected 8 to 10 
weeks after surgery, three times biweekly. Additional 
booster vaccinations are given at 3 and 6 months. Primary 
objective is to determine the feasibility of administering 
DCBI after CRS-HIPEC in patients with malignant peritoneal 
mesothelioma. Secondary objectives are to assess safety 
of DCBI in patients with peritoneal mesothelioma and 
determine whether a specific immunological response 
against the tumour occurs as a result of this adjuvant 
immunotherapy.
Ethics and dissemination Permission to carry out this 
study protocol has been granted by the Central Committee 
on Research Involving Human Subjects (CCMO in Dutch) 
and the Research Ethics Committee (METC in Dutch). The 
results of this trial will be submitted for publication in a 
peer-reviewed journal.
trial registration number NTR7060. EudraCT: 2017-
000897-12; Pre-Results.
IntroduCtIon
Malignant peritoneal mesothelioma (MPM) 
is a highly lethal neoplasm, arising from the 
strengths and limitations of this study
 ► The dendritic cell vaccines used in this protocol can 
be manufactured on a large scale, because autolo-
gous dendritic cells are loaded with allogeneic tu-
mour associated antigens.
 ► Dendritic cell based immunotherapy has shown to 
have very limited side effects, especially when com-
pared with systemic chemotherapy.
 ► This study will provide clinicians and scientists with 
important information about the immunological re-
sponse after dendritic cell vaccination.
 ► Since all patients undergo cytoreductive surgery and 
hyperthermic intraperitoneal chemotherapy prior to 
dendritic cell based immunotherapy (DCBI), the ef-
fect of DCBI must be determined by assessing the 
immune response and overall clinical condition of 
each patient.
 ► In this phase II clinical trial the effect of DCBI on dis-
ease-free and overall survival cannot be determined, 
when DCBI is considered safe and feasible, a phase 
III clinical trial will be conducted to determine the 
effect on survival.
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serosal lining of the peritoneal cavity. It has a strong asso-
ciation with exposure to asbestos. Non-specific clinical 
symptoms like weight loss, abdominal pain and disten-
sion contribute to a delay in diagnosis. As a result, the 
majority of MPM cases are identified at an advanced 
stage, creating an overall poor life-expectancy of 4 to 12 
months if left untreated.1 Even after (palliative) surgery 
and/or systemic chemotherapy, MPM has poor survival of 
approximately 1 year.
In recent years treatment focus has shifted towards a 
more aggressive approach, utilising cytoreductive surgery 
(CRS) and hyperthermic intraperitoneal chemotherapy 
(HIPEC). Patients that underwent this treatment had a 
better prognosis with median survival of 53 months and 
5 year survival of 47%.2 However, even after CRS-HIPEC, 
recurrence rates are high with reported median progres-
sion-free survival and disease-free survival ranging from 
11 to 28 months and 7.2 to 40 months respectively.1 One 
explanation is that it is difficult to perform complete 
cytoreduction, as MPM often grows diffusely throughout 
the abdominal cavity,3 but even when macroscopic 
complete cytoreduction is reached, loco-regional recur-
rence is often seen. A study that included 108 patients 
in whom complete or near-complete cytoreduction was 
achieved showed local recurrence in 38% of patients after 
median follow-up of 48.8 months.4
Effective adjuvant therapies are pressingly needed for 
above mentioned reasons. Dendritic cell based immuno-
therapy (DCBI) has shown promising results by harnessing 
the potency and specificity of the immune system. The first 
DCBI for mesothelioma was developed in the Erasmus 
MC, Rotterdam, and has been tested in murine models 
with peritoneal mesothelioma and in clinical phase I/II 
studies for patients with pleural mesothelioma.5–11 These 
studies have shown that DCBI induces durable responses 
and higher survival rates compared with the general 
mesothelioma population. Dendritic cell (DC) therapy 
was well tolerated in these patients without grade 3 or 
4 toxicities. Only low-grade fever and flu-like symptoms 
(grade 1 to 2) were seen for 24 hours after treatment. In 
a dose escalation phase I trial, the safety of using allo-
geneic tumour lysate (PheraLys) for the loading of the 
DCs was assessed. PheraLys is a tumour cell lysate derived 
from five well-characterised cell lines from patients with 
malignant mesothelioma. Tumour lysate priming strate-
gies may be advantageous in providing the full antigenic 
repertoire of the tumour and might reduce the possi-
bility of tumour escape by inducing a broader immune 
response. In this study adverse events were similar to 
earlier studies and importantly no severe adverse events 
were observed. Furthermore, clinical responses were 
established radiographically and some longtime survivors 
are being observed.
Previous preclinical studies demonstrated that DCBI 
has the capacity to slow down tumour growth, although 
tumour load has an important role in survival.12 Mice had 
a better outcome when DCs were injected early in tumour 
development.5 Mesothelioma cells produce specific 
cytokines and attract regulatory T-cells that suppress effi-
cient immune responses, indicating that patients with low 
tumour load have a better functioning immune system 
and better anti-tumour responses.13 Therefore it is the 
aim of this trial to treat patients with DCBI after complete 
macroscopic cytoreduction and HIPEC. The residual 
disease after cytoreductive surgery is classified using the 
the ‘completeness of cytoreduction’ (CCR score). CCR-0 
indicates no visible residual tumour and CCR-1 indi-
cates residual tumour nodules ≤2.5 mm. CCR-2 indicates 
residual tumour nodules between 2.5 mm and 2.5 cm. 
CCR-3 indicates a residual tumour >2.5 cm. In this study 
CCR ≤1 is considered as complete macroscopic cytore-
duction. However, when complete cytoreduction cannot 
be achieved during surgery, patients undergo palliative 
HIPEC followed by DCBI
Main objective of this clinical trial is to determine feasi-
bility of administering adjuvant DCBI after CRS-HIPEC. 
Secondary objectives are to asses safety and determine 
if a specific immunological response against the tumour 
occurs after DC therapy. When DCBI is considered safe 
and feasible as adjuvant treatment for patients with MPM, 
further research (phase III study) is warranted to deter-
mine the effect on survival.
MEthods And AnAlysIs
study design
Trial setting
The MESOPEC trial is an open-label, single arm, single 
centre phase II clinical trial. This study is conducted 
in the Erasmus MC, Rotterdam, an academic hospital 
located in the Netherlands. All patients included in this 
trial will receive adjuvant DCBI after CRS-HIPEC. Trial 
registration details are described in table 1.
Study population
The study population consists of adult patients diagnosed 
with MPM. Potentially eligible patients will be referred by 
their local clinician or through self-referral to a medical 
specialist and member of the study team to discuss the 
trial and determine eligibility.
In order to participate in the study, patients must meet 
the following inclusion criteria:
 ► Histologically or cytologically confirmed diagnosis of 
epithelioid MPM.
 ► WHO-Eastern Cooperative Oncology Group perfor-
mance status of 0 or 1.
 ► Normal organ function and adequate bone marrow 
reserve (absolute neutrophil count >1.0×109/l, platelet 
count >100×109/l, haemoglobin >6.0 mmol/L).
 ► Positive delayed -type hypersensitivity skin test against 
at least one positive control antigen tetanus toxoid.
 ► Planned start date of vaccination within 8 to 10 weeks 
after CRS-HIPEC.
 ► Expected survival prior to surgery must be at least 
6 months.
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Table 1 WHO trial registration data set
Primary registry and trial identifying 
number
EudraCT number: 2017-000897-12
Netherlands trial register: NTR7060
Date of registration in primary registry October 2017
Protocol version Protocol version 3.0, date 31-10-2017
SPIRIT guidelines data set for clinical trials See online supplementary file
Source(s) of monetary or material support Erasmus University Medical Centre, Rotterdam, the Netherlands
Dutch Cancer Society (KWF Kankerbestrijding)
Stichting Coolsingel
Primary sponsor Erasmus University Medical Centre, Rotterdam, the Netherlands
Secondary sponsors Dutch Cancer Society (KWF Kankerbestrijding)
Stichting Coolsingel
Contact for public queries N.L. de Boer, study coordinator
Department of surgical oncology
Erasmus MC, Rotterdam, the Netherlands
n.deboer@erasmusmc.nl, (+31)010–704 21 25
J.P. van Kooten, study coordinator
Department of surgical oncology
Erasmus MC, Rotterdam, the Netherlands
j.kooten@erasmusmc.nl, (+31)010–704 21 25
Contact for scientific queries E.V.E. Madsen, principal investigator
Department of surgical oncology
Erasmus MC, Rotterdam, the Netherlands
e.madsen@erasmusmc.nl, (+31)010–704 10 82
Public title Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery 
(CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal 
mesothelioma: the MESOPEC trial
Scientific title Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery 
(CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal 
mesothelioma: a phase II single centre open-label clinical trial
Countries of recruitment The Netherlands
Health conditions or problems studied Malignant peritoneal mesothelioma
Interventions Vaccination with autologous dendritic cells loaded with allogeneic mesothelioma 
specific tumour antigens, after standard care (CRS-HIPEC)
Key inclusion and exclusion criteria Inclusion criteria:
Confirmed diagnosis of epithelial peritoneal mesothelioma
WHO-ECOG performance status 0 to 1, expected survival at least 6 months
Adequate organ function and bone marrow reserves
Positive delayed type hypersensitivity skin test for positive control antigen
Exclusion criteria:
Extra-abdominal disease/metastatic disease
Current use of steroids or other immunosuppressive agents
Prior cytoreductive surgery
Prior malignancy other than basal cell carcinoma within 10 years of inclusion
Patients with a known allergy to shellfish
Serious chronic or acute illness considered to constitute unwarranted high risk for 
CRS-HIPEC or dendritic cell treatment
Pregnant or lactating women
Study type Open label single centre phase II study
Date of first enrolment March 2018
Target sample size 20
Recruitment status Recruiting
Primary outcome Feasibility (DCBI therapy is considered feasible when 75% of patients enrolled 
in this study are able to receive and finish dendritic cell vaccination after CRS-
HIPEC)
Continued
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 ► At least 18 years of age, written informed consent 
according to International Council for Harmoni-
sation-Good clinical practice (ICH-GCP), ability to 
return to the study centre for adequate follow-up.
A potential participant who meets any of the following 
criteria will be excluded from participation in the study:
 ► Extra-abdominal mesothelioma (ie, metastatic 
disease).
 ► Prior cytoreductive surgery.
 ► Prior malignancy other than basal cell carcinoma 
within 10 years of inclusion.
 ► Serious concomitant disease or infection, including 
HIV or chronic viral hepatitis.
 ► Current use of steroids or other immunosuppressive 
agents (at least 6 weeks discontinuation before the 
first vaccine, with exception of prophylactic usage of 
dexamethasone during chemotherapy).
 ► History of auto-immune disease or organ allografts.
 ► Any disease that is considered to constitute an unwar-
ranted high risk for CRS-HIPEC by the surgeon or 
study coordinator.
 ► Pregnant or lactating women.
Patient timeline and additional procedures
Patients will undergo leukapheresis for dendritic cell 
vaccine production purposes 4 to 6 weeks before surgery. 
At baseline, subjects will undergo CRS-HIPEC.
At 6 weeks after surgery, the investigators will deter-
mine if the patient is sufficiently recovered and fit to 
undergo DCBI. Patients must have adequate bone 
marrow reserve before DCBI treatment; absolute neutro-
phil count >1.0×109/l, platelet count >100×109/l and 
haemoglobin >6.0 mmol/L.
Dendritic cell vaccinations will be given at 8 to 10 weeks 
after surgery three times biweekly. Before each vacci-
nation laboratory testing will be performed and results 
reviewed before injection. Before and after injection 
vital signs (pulse, blood pressure, blood oxygen satu-
ration and temperature) are determined. Patients are 
observed in the hospital for 2 hours after injection. Each 
vaccine contains at least 25×106 cells. One-third of this 
is injected intradermal, two-thirds are administered intra-
venous. Intradermal injection will be performed in the 
left arm. Intravenous injection will be performed via the 
vena brachialis in the left arm through a basic peripheral 
venous catheter. After the third vaccination, delayed-
type hypersensitivity (DTH) skin test is performed. 
When DTH skin test result is positive for the dendritic 
cell vaccine, a 3 mm skin biopsy will be taken for further 
analyses. At 3 and 6 months after the first vaccination, two 
additional booster vaccinations will be given. Additional 
to study-related treatment, patients receive standard care 
and follow-up required after CRS-HIPEC.
Total duration of the treatment protocol is 8 to 
9 months. In total, 11 additional visits are required to 
adhere to the study protocol. For the production of 
DCBI patients undergo leukapheresis. For the purpose 
of immune-monitoring, additional blood samples will be 
collected at seven moments during the study. (figure 1)
Dendritic cell vaccine production
Dendritic cells are derived from peripheral blood mono-
nuclear cells, by differentiating monocytes towards imma-
ture dendritic cells using specific cytokines. Immature 
dendritic cells are known for their high antigen uptake 
potential. Therefore they are exposed to tumour specific 
antigens in a co-culture with allogeneic mesothelioma 
cell lysate. This lysate (PheraLys) is derived from five 
well-specified mesothelioma cell lines. After exposure to 
PheraLys the immature dendritic cells are differentiated 
towards mature dendritic cells, which are ready to activate 
the immune system in vivo (MesoPher). (figure 2)
Withdrawal of individual subjects
Subjects can leave the study at any time for any reason if 
they wish to do so without any consequences. The investi-
gator can decide to withdraw a subject from the study for 
urgent medical reasons. Should a participant withdraw 
from the trial, then every effort will be made to obtain 
follow-up data, with the permission of the patient.
The investigators also have the right to withdraw 
patients from the study if one or more of the following 
events occur:
 ► Significant protocol violation or non-compliance on 
the part of the patient or investigator.
 ► Refusal of the patient to continue treatment or 
observations.
 ► Any change in the condition of the patient that justi-
fies discontinuation of treatment.
 ► Decision by the study coordinator that MesoPher does 
not comply to quality requirements (advice of quali-
fied person).
 ► Decision by the study coordinator that termination is 
in the patient’s best medical interest.
 ► Unrelated medical illness or complication.
Primary registry and trial identifying 
number
EudraCT number: 2017-000897-12
Netherlands trial register: NTR7060
Key secondary outcome(s) Safety
Immunological response after dendritic cell vaccination
CRS, cytoreductive surgery; ECOG, Eastern Cooperative Oncology Group; HIPEC, hyperthermic intraperitoneal chemotherapy; SPIRIT, 
Standard Protocol Items: Recommendations for Interventional Trials. 
Table 1 Continued 
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 ► Serious logistical problems of practical problems in 
clean room.
objectives and analysis
Primary objective
Primary objective is to determine feasibility of using DCBI 
after CRS-HIPEC in patients with peritoneal mesothe-
lioma. DCBI after CRS-HIPEC is deemed feasible when 
at least 75% of patients that are included in this trial 
complete the full treatment schedule. This cut-off is based 
on the fact that currently around 75% of patients under-
going CRS-HIPEC are fit to undergo adjuvant therapy, 
such as systemic chemotherapy.
Secondary objectives
Secondary objectives are to assess safety of DCBI therapy 
after CRS-HIPEC and determine whether a specific 
immunological response occurs due to dendritic cell 
vaccination.
Figure 1 Patient timeline: In total 11 additional visits are required. After informed consent is acquired, screening will take 
place in the form of full examination and DTH skin test. When patients comply to all criteria, they will undergo leukapheresis for 
production of dendritic cell vaccine. After 2 to 4 weeks patients undergo CRS-HIPEC. First vaccination is given 8 to 10 weeks 
after surgery, followed by two more vaccinations biweekly. DTH skin testing is performed for analysis of immune response 2 
weeks after the third vaccination. At 3 and 6 months after first vaccination, subjects receive additional ‘booster’ vaccination. 
Each vaccine contains at least 25×106 cells. One-third is injected intradermal. Two-thirds are administered intravenous. ANCA, 
anti-neutrophil cytoplasmic antibody; CRS, cytoreductive surgery; CT, computed tomography; DC, dendritic cell; DTH, delayed-
type hypersensitivity; HIV, human immunodeficiency virus; HIPEC, hyperthermic intraperitoneal chemotherapy; MPM, malignant 
peritoneal mesothelioma; RBC, red blood cell; WBC, white blood cell. 
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Safety
Previous clinical studies have shown that injection with 
tumour lysate-pulsed autologous DCs was overall well 
tolerated without systemic toxicity, with the exception of 
low-grade flu-like symptoms like fever and rigours. No 
grade 3 or 4 toxicity was observed.11 However, safety and 
tolerability after major surgery has yet to be determined.
The administration of autologous cells that have been 
loaded with allogeneic human materials is a potential 
health risk. Because not the lysate itself is administered to 
the patients, but only after it has been processed by autol-
ogous dendritic cells, risks are expected to be limited.
The necessary sample size for the detection of grade 
3 toxicity is calculated to be 20 patients (figure 3). All 
adverse events, serious adverse events and suspected 
unexpected serious adverse reactions will be monitored 
and reported by the sponsor.
Immune response
Assessment of immune responses will be conducted on 
three levels in all treated patients; (1) responses that 
mark successful vaccination, (2) enhanced frequencies 
of tumor-specific T cells in peripheral blood samples and 
(3) frequency shifts in other immune cell subsets.
1. Keyhole limpet hemocyanin (KLH) is added to the 
vaccines as a surrogate marker. With the use of KLH, 
we will assess whether an immune response against 
the vaccine has occurred and whether this response 
persists. KLH is known to induce a specific adaptive 
immune response readily detectable in sera (antibody 
response) and skin tests (cellular response) of vacci-
nated individuals. Serum samples will be collected 
before, during and after DCBI as well as at selected in-
tervals during follow-up. Humoral responses to KLH 
will be detected using ELISA. Furthermore, patients 
will undergo a DTH skin test before and after DCBI. 
DTH responses will be evaluated for local inflamma-
tion after 48 hours and 3 mm punch biopsies will be 
collected in case inflammation occurs. These biopsies 
will subsequently be used for in situ immunostainings 
of DC, myeloid derived suppressor cells (MDSC), and 
CD8 +T cells.
2. To assess vaccine-induced frequencies of tumor-specif-
ic T cells, we will conduct a potency assay in accordance 
with the ‘Guideline on potency testing of cell based im-
munotherapy medicinal products for the treatment of 
cancer’ as provided by the European Medicine Agen-
cy (EMA) in 2016 (EMA/CHMP/BWP/271475/2006 
rev.1). The proposed assay can shortly be described as 
a co-culture of T cells isolated from pre- and post-treat-
ment peripheral blood samples with autologous DCs 
loaded with autologous tumour lysate. Subsequent-
Figure 2 DCBI production process: Monocytes are isolated from peripheral blood and are then stimulated to differentiate 
towards immature dendritic cells. These immature dendritic cells are exposed to PheraLys tumour cell lysate. After further 
differentiation towards mature dendritic cells, MesoPher vaccinations are given back to the patient. DCBI, dendritic cell based 
immunotherapy. 
Figure 3 Sample size calculation: Assuming the sensitivity 
for detecting grade 3 (or higher) toxicity is 99%. Expected 
prevalence of grade 3 toxicity in the study population is 
2.5%.
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ly, we will measure T cell proliferation and activation 
markers via multicolour flow cytometry.
3. Phenotypical analysis of immune cell subsets will be 
conducted using flow cytometry to detect vaccine-in-
duced changes in the frequencies of >100 immune 
cell (subsets) that represent distinct lineages and/or 
express different levels of activation, differentiation 
and co-signalling markers. Staining of fresh patient 
material at different time points will allow enumera-
tion of different immune cells throughout therapy. 
Subsequent bulk analysis of frozen material focusses 
solely on an extensive array of T cell, MDSC and DC 
markers. Combination of these readouts allows for the 
generation of immune profiles for individual patients. 
The analysis of these profiles in turn will allow for the 
determination of prospective markers and better strat-
ification of patient populations suited for vaccination 
therapy.
statistical analysis
The statistical analyses/data summaries will be performed 
using SPSS. Other tools may be used for exploratory 
summaries and graphical presentations.
Primary endpoint is to determine the feasibility of 
administering DCBI after CRS-HIPEC in patients with 
malignant peritoneal mesothelioma. Based on previous 
results it is known that from all patients with colorectal 
carcinoma that underwent CRS-HIPEC, about 25% is not 
able to receive adjuvant systemic therapy due to postop-
erative complications. Feasibility is set if 15 of 20 patients 
(75%) were able to undergo leukapheresis successfully, 
production of PheraLys and dendritic cell vaccines was 
successful and when patients were able to complete the 
full adjuvant treatment schedule.
Patient and public involvement
The Dutch patient association for patients with meso-
thelioma ‘Instituut Asbestslachtoffers’ and the Erasmus 
MC, Rotterdam, have worked together closely for years 
on the development of dendritic cell immunotherapy 
for mesothelioma. The patient association has received 
a copy of the study protocol to comment on the research 
question and outcome measures and also received the 
patient information folder to comment on patients pref-
erence and clarity of the information folder. During the 
study, feedback is provided on the inclusion rate and 
patient experiences. The results of the study will also be 
communicated to the patient association, which can then 
distribute them among their members.
EthICs And dIssEMInAtIon
The study will be conducted in compliance with the 
‘Medical Research Involving Human Subjects Act’ 
(WMO) and according to the principles of the Declara-
tion of Helsinki (64th World Medical Association General 
Assembly, Fortaleza, Brazil, October 2013).
If protocol modifications occur, the new protocol has 
to be approved by the Central Committee on Research 
Involving Human Subjects and the Research Ethics 
Committee of the Erasmus MC before they can be imple-
mented. Data collection, data assessment and data anal-
ysis will be performed according to the local guidelines 
for data management of the Erasmus MC.
To generate more awareness for this current study and 
to increase referrals of potential study candidates to the 
Erasmus MC, a short Dutch summary of the study will be 
submitted to The Dutch Journal for Oncology (NTVO 
in Dutch). Also, presentations about the study have 
been given at the Dutch Society of Surgery meeting and 
the Peritoneal Surface Oncology Group International 
meeting in Paris.
The results of this clinical trial will be submitted for 
publication in a peer-reviewed scientific journal.
The investigator will permit auditors to carry out site 
visits to audit the compliance with regulatory guidelines. 
Similar auditing procedures may be conducted by agents 
of any regulatory body reviewing the results of this study.
The sponsor will submit a yearly safety report to the 
accredited METC, competent authority and compe-
tent authorities of the concerned Member States. This 
safety report consists of; 1 a list of all suspected (unex-
pected or expected) serious adverse reactions, 2 a report 
concerning the safety of the subjects consisting of a 
complete safety analysis and an evaluation of the balance 
between the efficacy and the harmfulness of the medicine 
under investigation.
Within 1 year after the end of the study, the investi-
gator/sponsor will submit a final study report with the 
results of the study, including any publications/abstracts 
of the study, to the accredited METC and the Competent 
Authority.
Currently three patients are included in the study 
protocol. The final patient is expected to be included at 
the end of 2020. First results are expected in 2021.
dIsCussIon
The main objective of the MESOPEC trial is to determine 
feasibility of DCBI as adjuvant treatment after CRS-HIPEC 
in patients with MPM. Secondary objectives are to assess 
safety and to monitor the immune response after DCBI. 
The MESOPEC trial is the first clinical trial offering adju-
vant dendritic cell immunotherapy to patients with MPM. 
So far (neo)adjuvant systemic chemotherapy has shown 
no benefit on surgical or oncological outcome for MPM.14 
Systemic chemotherapy, using cisplatin and pemetrexed, 
is standard treatment in pleural mesothelioma and has 
been applied to patients with peritoneal mesothelioma. 
This has shown limited efficacy, considerable toxicity 
and even mortality, making it unfit for the treatment of 
MPM.15
The DCBI used in this current trial consists of person-
alised dendritic cell vaccines, produced with autologous 
dendritic cells that are loaded with tumour associated 
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antigens derived from allogeneic tumour cell lysate. This 
treatment approach has multiple advantages. The biggest 
advantage of this strategy is that it is possible to produce 
personalised anti-cancer vaccines on a scale sufficient 
for clinical implementation in larger groups of patients. 
Another advantage is that so far DCBI has shown no 
severe side effects and therefore causes little morbidity 
especially when compared with current other adjuvant 
treatment options, like systemic chemotherapy.
Analyses of tissue and blood samples that are collected 
throughout the study will provide valuable information 
for scientists and clinicians regarding the immunologic 
response after DCBI. Furthermore, potential of DCBI can 
be tested in vitro by culturing tumour cell lines derived 
from tumour tissue obtained during CRS. By doing so, in 
the future, patients that will respond to immunotherapy 
can be identified before starting treatment.
Currently, CRS-HIPEC is the gold standard for a 
selected group of patients suffering from MPM. Eligibility 
for CRS-HIPEC is dependent on several clinical aspects 
such as ‘peritoneal carcinoma index’ (PCI), histological 
subtype and overall patient health condition. Previous 
studies have shown that outcome after CRS-HIPEC 
strongly depends on the completeness of cytoreduction.1 
Unfortunately it is very difficult to achieve complete 
cytoreduction in patients with high PCI score. It has been 
reported by others that immunotherapy is possibly more 
effective in patients with low tumour load. Therefore, 
in this study DCBI is given as adjuvant treatment after 
CRS-HIPEC. However, if a significant clinical effect can 
be achieved, in the future DCBI might be used as a neoad-
juvant therapy making CRS-HIPEC with complete cytore-
duction available for a larger number of patients.
We acknowledge the fact that this study has limita-
tions. One limitation of this study is the small number of 
patients that will be included. Given the rarity of MPM, it 
is difficult to include large numbers of patients. However 
the sample size of this current study, should be sufficient 
to determine the feasibility and safety of adjuvant DCBI 
after CRS-HIPEC.
Another limitation of this study design is that it is not 
possible to determine radiological response to DCBI 
treatment. After debulking surgery, MPM will not be 
detectable on CAT scans. Therefore the response to DCBI 
treatment must be determined by assessing the immune 
response and overall clinical condition of each patient. 
Clinical effect of DCBI on overall survival can only be 
determined after a longer period of follow-up.
If DCBI is considered feasible as adjuvant treatment 
for MPM, a larger phase III clinical trial should be 
conducted to determine the effect on surgical and onco-
logical outcome. Because MPM incidence in the Nether-
lands alone is very low, this clinical trial would have to be 
conducted internationally.
Author affiliations
1Surgical Oncology, Erasmus MC, Rotterdam, Zuid-Holland, The Netherlands
2Pulmonary Medicine, Erasmus MC, Rotterdam, Zuid-Holland, The Netherlands
Correction notice This article has been corrected since it first published online. 
The open access licence type has been amended. 
Acknowledgements We would like to thank the Dutch patient association for 
patients with mesothelioma for their detailed advice and guidance during the 
design of this study. 
Contributors NLdB and JPvK drafted this manuscript. NLdB, JWAB, JGJVA, CV and 
EVEM drafted the original study protocol and revised the manuscript. CV, JGJVA 
and EVEM initiated the trial and supervised the drafting of the study protocol and 
manuscript. EVEM acquired funding for implementation of the trial protocol and is 
the primary clinical investigator. All authors approved the final manuscript.
Funding This work was supported by: The Dutch Cancer Society (in Dutch: KWF 
Kankerbestrijding), grant number: 10246, Stichting Coolsingel, grant number: 482
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
rEFErEnCEs
 1. Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and 
hyperthermic intraperitoneal chemotherapy for malignant peritoneal 
mesothelioma: a systematic review and meta-analysis. Ann Surg 
Oncol 2015;22:1686–93.
 2. Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and 
hyperthermic intraperitoneal chemotherapy for malignant peritoneal 
mesothelioma: multi-institutional experience. J Clin Oncol 
2009;27:6237–42.
 3. Yan TD, Welch L, Black D, et al. A systematic review on the efficacy 
of cytoreductive surgery combined with perioperative intraperitoneal 
chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann 
Oncol 2007;18:827–34.
 4. Baratti D, Kusamura S, Cabras AD, et al. Diffuse malignant peritoneal 
mesothelioma: long-term survival with complete cytoreductive 
surgery followed by hyperthermic intraperitoneal chemotherapy 
(HIPEC). Eur J Cancer 2013;49:3140–8.
 5. Hegmans JP, Hemmes A, Aerts JG, et al. Immunotherapy of murine 
malignant mesothelioma using tumor lysate-pulsed dendritic cells. 
Am J Respir Crit Care Med 2005;171:1168–77.
 6. Hegmans JP, Veltman JD, Lambers ME, et al. Consolidative dendritic 
cell-based immunotherapy elicits cytotoxicity against malignant 
mesothelioma. Am J Respir Crit Care Med  
2010;181:1383–90.
 7. Veltman JD, Lambers ME, van Nimwegen M, et al. Low-
dose cyclophosphamide synergizes with dendritic cell-based 
immunotherapy in antitumor activity. J Biomed Biotechnol 
2010;2010:1–10.
 8. Cornelissen R, Heuvers ME, Maat AP, et al. New roads open up for 
implementing immunotherapy in mesothelioma. Clin Dev Immunol 
2012;2012:1–13.
 9. Heuvers ME, Wisnivesky J, Stricker BH, et al. Generalizability of 
results from the National Lung Screening Trial. Eur J Epidemiol 
2012;27:669–72.
 10. Cornelissen R, Lievense LA, Heuvers ME, et al. Dendritic cell-based 
immunotherapy in mesothelioma. Immunotherapy  
2012;4:1011–22.
 11. Cornelissen R, Hegmans JP, Maat AP, et al. Extended tumor control 
after dendritic cell vaccination with low-dose cyclophosphamide as 
adjuvant treatment in patients with malignant pleural mesothelioma. 
Am J Respir Crit Care Med 2016;193:1023–31.
 12. Anguille S, Smits EL, Lion E, et al. Clinical use of dendritic cells for 
cancer therapy. Lancet Oncol 2014;15:e257–e267.
 13. Hegmans JP, Hemmes A, Hammad H, et al. Mesothelioma 
environment comprises cytokines and T-regulatory cells that 
suppress immune responses. Eur Respir J 2006;27:1086–95.
 14. Deraco M, Baratti D, Hutanu I, et al. The role of perioperative 
systemic chemotherapy in diffuse malignant peritoneal mesothelioma 
patients treated with cytoreductive surgery and hyperthermic 
intraperitoneal chemotherapy. Ann Surg Oncol 2013;20:1093–100.
 o
n
 7 August 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026779 on 14 May 2019. Downloaded from 
9de Boer NL, et al. BMJ Open 2019;9:e026779. doi:10.1136/bmjopen-2018-026779
Open access
 15. Jänne PA, Wozniak AJ, Belani CP, et al. Open-label study of 
pemetrexed alone or in combination with cisplatin for the treatment 
of patients with peritoneal mesothelioma: outcomes of an expanded 
access program. Clin Lung Cancer 2005;7:40–6.
 o
n
 7 August 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026779 on 14 May 2019. Downloaded from 
